Linked Life Data

20358485

Source:http://linkedlifedata.com/resource/pubmed/id/20358485

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-4-1
pubmed:abstractText
Recently, the list of clinical applications of botulinum toxin type A (BTX-A) enlarged. This medication is used not only by neurologists, but also by medical rehabilitation specialists, urologists, proctologists, and migraine and aesthetic medicine specialists. Currently, there are three commercially available BTX-A preparations available: Botox, Dysport and Xeomin. They have similar mechanisms of action but their chemical formulation, clinical potency, migration and diffusion as well as safety profile seem to be different. This may result in problems of bioequivalence, not only clinical but also economic ones. The authors reviewed the available clinical and laboratory studies on neurological indications labelled in Poland. Each BTX-A formulation should be treated as a different medication and used cautiously according to the individual range of dosages established in clinical trials.
pubmed:language
pol
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0028-3843
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
43-64
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:articleTitle
[Are botulinum toxin type A preparations really the same medication? A comparison of three botulinum toxin A for variations in labelled neurological indications].
pubmed:affiliation
Zak?ad Pielegniarstwa Neurologiczno-Psychiatrycznego, Gda?ski Uniwersytet Medyczny, Szpital Specjalistyczny ?w. Wojciecha, Al. Jana Paw?a II, Gda?sk, Poland. jaroslawek@gumed.edu.pl
pubmed:publicationType
Journal Article, Comparative Study, English Abstract, Review